BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 26416247)

  • 21. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling.
    Wang X; Lu X; Geng Z; Yang G; Shi Y
    J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
    Lee G; Kang YE; Oh C; Liu L; Jin Y; Lim MA; Won HR; Chang JW; Koo BS
    Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
    Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway.
    Qu N; Hu JQ; Liu L; Zhang TT; Sun GH; Shi RL; Ji QH
    Int J Oncol; 2017 May; 50(5):1683-1692. PubMed ID: 28393212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of β-catenin/E-cadherin signaling.
    Cho SW; Lee EJ; Kim H; Kim SH; Ahn HY; Kim YA; Yi KH; Park DJ; Shin CS; Ahn SH; Cho BY; Park YJ
    Mol Cell Endocrinol; 2013 Feb; 366(1):90-8. PubMed ID: 23261982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients.
    Zhang J; Cai H; Sun L; Zhan P; Chen M; Zhang F; Ran Y; Wan J
    J Exp Clin Cancer Res; 2018 Sep; 37(1):225. PubMed ID: 30208924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
    Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
    PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

  • 34. miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.
    Wen Q; Zhao J; Bai L; Wang T; Zhang H; Ma Q
    Oncol Rep; 2015 Oct; 34(4):2202-10. PubMed ID: 26239517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
    Park HS; Jung CK; Lee SH; Chae BJ; Lim DJ; Park WC; Song BJ; Kim JS; Jung SS; Bae JS
    Cancer Sci; 2012 Feb; 103(2):305-9. PubMed ID: 22118425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
    Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.
    Sun W; Lan X; Wang Z; Dong W; He L; Zhang T; Zhang H
    Med Oncol; 2016 Sep; 33(9):102. PubMed ID: 27510368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
    Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
    Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.